"Even in this time of uncertainty, Mayo Clinic is a place for hope and healing — and we're delivering the care you need. Mayo Clinic follows carefully designed, rigorously enforced safety precautions for anyone who needs face-to-face care. We're safely treating all patients, both in person and through virtual visits, in adherence with federal and state executive orders and guidance. The Mayo Clinic Building in Phoenix is home to multiple specialties. It brings together expert physicians, dedicated and specialized multi-disciplinary care teams, and the most effective medicine all under one roof. The Mayo Clinic Building bolsters Mayo Clinic's commitment to providing an environment that fosters teamwork and promotes wellness and recovery."

During the past decade, Mayo Clinic Building - Phoenix conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mayo Clinic Building - Phoenix" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Mayo Clinic Building - Phoenix" are "Metastatic Colorectal Cancer" (1 trials) and "Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis" (1 trials). Many other conditions were trialed in "Mayo Clinic Building - Phoenix" in a lesser frequency.

Most popular intervention types in "Mayo Clinic Building - Phoenix" are "Drug" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cetuximab" (1 trials), "Encorafenib" (1 trials), "Glasdegib (PF-04449913)" (1 trials), "Pembrolizumab" (1 trials) and "Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Mayo Clinic Building - Phoenix" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Mayo Clinic Building - Phoenix". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Mayo Clinic Building - Phoenix, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Mayo Clinic Building - Phoenix, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".